NO973027L - Nye kinuklidinderivater og medisinsk preparat - Google Patents

Nye kinuklidinderivater og medisinsk preparat

Info

Publication number: NO973027L
Authority: NO; Norway
Prior art keywords: quinuclidine derivatives; medical preparations; diseases; new quinuclidine; new
Prior art date: 1994-12-28

Application number

NO973027A

Other languages

English (en)

Other versions

NO973027D0 (no

NO318026B1 (no

Inventor

Makoto Takeuchi

Ryo Naito

Masahiko Hayakawa

Yoshinori Okamoto

Tasuhiro Yonetoku

Ken Ikeda

Yasuo Isomura

Original Assignee

Yamanouchi Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-28

Filing date

1997-06-27

Publication date

1997-08-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18194699&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO973027(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-27 Application filed by Yamanouchi Pharma Co Ltd filed Critical Yamanouchi Pharma Co Ltd

1997-06-27 Publication of NO973027D0 publication Critical patent/NO973027D0/no

1997-08-28 Publication of NO973027L publication Critical patent/NO973027L/no

2005-01-24 Publication of NO318026B1 publication Critical patent/NO318026B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K19/00—Liquid crystal materials
- C09K19/04—Liquid crystal materials characterised by the chemical structure of the liquid crystal components, e.g. by a specific unit
- C09K19/06—Non-steroidal liquid crystal compounds
- C09K19/34—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring
- C09K19/3441—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom
- C09K19/3444—Non-steroidal liquid crystal compounds containing at least one heterocyclic ring having nitrogen as hetero atom the heterocyclic ring being a six-membered aromatic ring containing one nitrogen atom, e.g. pyridine

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Pulmonology (AREA)
Materials Engineering (AREA)
Urology & Nephrology (AREA)
Crystallography & Structural Chemistry (AREA)
Rheumatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
External Artificial Organs (AREA)
Tea And Coffee (AREA)

NO19973027A 1994-12-28 1997-06-27 Kinuklidinderivat og farmasoytisk preparat NO318026B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP32704594		1994-12-28
PCT/JP1995/002713 WO1996020194A1 (en)	1994-12-28	1995-12-27	Novel quinuclidine derivatives and medicinal composition thereof

Publications (3)

Publication Number	Publication Date
NO973027D0 NO973027D0 (no)	1997-06-27
NO973027L true NO973027L (no)	1997-08-28
NO318026B1 NO318026B1 (no)	2005-01-24

Family

ID=18194699

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO2005012C NO2005012I1 (no)	1994-12-28	1988-09-19	Triptorelin og farmasoytisk akseptable salter derav
NO19973027A NO318026B1 (no)	1994-12-28	1997-06-27	Kinuklidinderivat og farmasoytisk preparat
NO2005016C NO2005016I2 (no)	1994-12-28	2005-07-11	Solifenacin og/eller et farmasoytisk syreaddisjonssalt derav
NO2017055C NO2017055I2 (no)	1994-12-28	2017-11-06	Solifenacin og/eller et farmasøytisk syreaddisjonssalt derav - forlenget SPC

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO2005012C NO2005012I1 (no)	1994-12-28	1988-09-19	Triptorelin og farmasoytisk akseptable salter derav

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
NO2005016C NO2005016I2 (no)	1994-12-28	2005-07-11	Solifenacin og/eller et farmasoytisk syreaddisjonssalt derav
NO2017055C NO2017055I2 (no)	1994-12-28	2017-11-06	Solifenacin og/eller et farmasøytisk syreaddisjonssalt derav - forlenget SPC

Country Status (24)

Country	Link
US (2)	US6017927A (no)
EP (1)	EP0801067B1 (no)
JP (1)	JP3014457B2 (no)
KR (1)	KR100386487B1 (no)
CN (1)	CN1045601C (no)
AT (1)	ATE233761T1 (no)
AU (1)	AU695616B2 (no)
CA (1)	CA2208839C (no)
DE (2)	DE122004000048I2 (no)
DK (1)	DK0801067T3 (no)
ES (1)	ES2193208T3 (no)
FI (1)	FI115631B (no)
FR (1)	FR04C0032I2 (no)
HU (1)	HU223778B1 (no)
LU (1)	LU91133I9 (no)
MX (1)	MX9704880A (no)
NL (1)	NL300141I1 (no)
NO (4)	NO2005012I1 (no)
NZ (1)	NZ298144A (no)
PL (1)	PL182344B1 (no)
PT (1)	PT801067E (no)
RU (1)	RU2143432C1 (no)
TW (1)	TW305842B (no)
WO (1)	WO1996020194A1 (no)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100137358A1 (en) *	1996-11-05	2010-06-03	Dr. Reddy's Laboratories Ltd.	Solifenacin compositions
FR2772378B1 (fr) *	1997-12-12	2000-02-04	Synthelabo	Derives d'imidazole, leur preparation et leur application en therapeutique
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US7214687B2 (en)	1999-07-14	2007-05-08	Almirall Ag	Quinuclidine derivatives and medicinal compositions containing the same
JP2001316670A (ja) *	2000-05-02	2001-11-16	Dainippon Ink & Chem Inc	液晶組成物
DK1300407T4 (da) *	2000-06-27	2011-09-05	S A L V A T Lab Sa	Carbamater afledt af arylalkylaminer
HUP0303529A3 (en) *	2000-12-22	2008-03-28	Almirall Ag	New quinuclidine carbamate derivatives, process for their preparation and pharmaceutical compositions containing them and their use
SK287414B6 (sk)	2000-12-28	2010-09-07	Laboratorios Almirall, S.A.	Chinuklidínové deriváty a kompozície s ich obsahom
DK1405638T3 (da) *	2001-07-10	2011-04-18	Astellas Pharma Inc	Farmaceutisk sammensætning omfattende quinuclidin-3'-yl-1-phenyl-1,2,3,4,-tetrahydroisoquinolin-2-carboxylat til behandling af interstitiel cystitis og/eller abakteriel prostatitis
EP1461336B1 (en)	2001-12-20	2013-05-22	CHIESI FARMACEUTICI S.p.A.	1-alkyl-1-azoniabicyclo (2.2.2) octane carbamate derivatives and their use as muscarinic receptor antagonists
EP1552825A4 (en) *	2002-06-07	2009-11-25	Astellas Pharma Inc	THERAPEUTIC AGENT FOR THE TREATMENT OF VESIC HYPERACTIVITY
ES2203327B1 (es) *	2002-06-21	2005-06-16	Almirall Prodesfarma, S.A.	Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es)	2002-07-02	2005-08-01	Almirall Prodesfarma, S.A.	Nuevos derivados de quinuclidina-amida.
DE60230683D1 (de)	2002-07-08	2009-02-12	Ranbaxy Lab Ltd	3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
HK1079787A1 (zh)	2002-07-31	2006-04-13	Ranbaxy Laboratories Limited	用作毒蕈碱受体拮抗剂的3，6-二取代的氮杂双环[3．1．0]己烷衍生物
EP1545508A4 (en)	2002-08-09	2009-11-25	Ranbaxy Lab Ltd	3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
US7288562B2 (en)	2002-08-23	2007-10-30	Ranbaxy Laboratories Limited	Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo (3.1.0) hexane derivatives as muscarinic receptor antagonists
AU2003269380A1 (en) *	2002-10-29	2004-05-25	Pharmacia & Upjohn Company Llc	Quinuclidinium derivatives as antimuscarinic agents
US7232835B2 (en)	2002-12-10	2007-06-19	Ranbaxy Laboratories Limited	3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
ES2288641T3 (es) *	2002-12-20	2008-01-16	Dynogen Pharmaceuticals Inc.	Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
US7465751B2 (en)	2002-12-23	2008-12-16	Ranbaxy Laboratories Limited	1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
WO2004056811A1 (en) *	2002-12-23	2004-07-08	Ranbaxy Laboratories Limited	Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en)	2003-01-28	2009-02-10	Ranbaxy Laboratories Limited	3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
DE602004003172T2 (de) *	2003-03-21	2007-09-27	Dynogen Pharmaceuticals Inc., Waltham	Verfahren zur behandlung von erkrankungen der unteren harnwege mit antimuskarinika und mit modulatoren der alpha-2-delta untereinheit des kalziumkanals
WO2004089898A1 (en)	2003-04-09	2004-10-21	Ranbaxy Laboratories Limited	Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
EP1615634B1 (en)	2003-04-10	2007-05-16	Ranbaxy Laboratories, Ltd.	Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003223010A1 (en)	2003-04-10	2004-11-01	Ranbaxy Laboratories Limited	Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
US20070021487A1 (en)	2003-04-11	2007-01-25	Mohammad Salman	Azabicyclo derivatives as muscarinic receptor antagonists
WO2004091597A2 (en) *	2003-04-15	2004-10-28	Pharmacia & Upjohn Company Llc	Method of treating irritable bowel syndrome (ibs)
US20050175689A1 (en) *	2003-10-27	2005-08-11	Yamanouchi Pharmaceutical Co., Ltd.	Coated fine particles containing drug for intrabuccally fast disintegrating tablet
JPWO2005075474A1 (ja) *	2004-02-09	2007-10-11	アステラス製薬株式会社	コハク酸ソリフェナシン含有組成物
WO2005077364A1 (ja) *	2004-02-18	2005-08-25	Yamanouchi Pharmaceutical Co., Ltd.	ソリフェナシンの経皮投与製剤およびその経皮透過改善方法
ES2239546B1 (es) *	2004-03-15	2006-12-01	Almirall Prodesfarma, S.A.	Nuevos esteres de quinuclidina cuaternizados.
CA2560080A1 (en) *	2004-03-16	2005-09-22	Astellas Pharma Inc.	Solifenacin-containing composition
JPWO2005087231A1 (ja) *	2004-03-16	2008-01-24	アステラス製薬株式会社	ソリフェナシン含有組成物
PT2156824E (pt)	2004-03-25	2013-01-04	Astellas Pharma Inc	Uma composição de solifenacina, ou um seu sal, utilizada sob a forma de formulações sólidas
ZA200608614B (en) *	2004-03-25	2008-06-25	Astellas Pharma Inc	Composition for solid pharmaceutical preparation of solifenacin or salt thereof
SE0400970D0 (sv) *	2004-04-14	2004-04-14	Astrazeneca Ab	Nicotinic acetylcholine receptor ligands
WO2006035280A1 (en) *	2004-09-27	2006-04-06	Ranbaxy Laboratories Limited	3,4-dihydroisoquinoline compounds as muscrinic receptor antagonists for the treatment of respiratory, urinary and gastrointestinal diseases
US20090105221A1 (en) *	2004-09-29	2009-04-23	Ranbaxy Laboratories Limited	Muscarinic receptor antagonists
MX2007007328A (es) *	2004-12-22	2007-07-25	Memory Pharm Corp	Ligandos del receptor alfa-7 nicotinico y preparacion y sus usos.
BG1677U1 (bg) *	2004-12-27	2013-04-30	Astellas Pharma Inc.Astellas Pharma Inc.	Фармацевтичен състав със стабилни частици на солифенацин или негова сол
CA2591761A1 (en) *	2004-12-27	2006-07-06	Astellas Pharma Inc.	Stable particulate pharmaceutical composition of solifenacin or salt thereof
EP1852117A4 (en) *	2005-02-25	2010-10-27	Astellas Pharma Inc	PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN
JP3701964B1 (ja)	2005-03-08	2005-10-05	アステラス製薬株式会社	キヌクリジン誘導体の新規な塩
US20080255188A1 (en) *	2005-07-11	2008-10-16	Naresh Kumar	Muscarinic Receptor Antagonists
US7815939B2 (en) *	2005-07-20	2010-10-19	Astellas Pharma Inc.	Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
WO2007045979A1 (en)	2005-10-19	2007-04-26	Ranbaxy Laboratories Limited	Pharmaceutical compositions of muscarinic receptor antagonists
JP2008535931A (ja) *	2005-12-21	2008-09-04	テバファーマシューティカルインダストリーズリミティド	ソリフェナシンの調製方法
CZ300699B6 (cs) *	2006-06-21	2009-07-22	Zentiva, A. S.	Zpusob prípravy solifenacinu
US20090326230A1 (en) *	2006-07-19	2009-12-31	Dr. Reddy's Laboratories Ltd.	Process for preparing solifenacin and its salts
ES2298049B1 (es) *	2006-07-21	2009-10-20	Laboratorios Almirall S.A.	Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
EP2043639A2 (en) *	2006-07-24	2009-04-08	Teva Pharmaceutical Industries Ltd.	Processes for preparing polymorphic forms of solifenacin succinate
US20080114029A1 (en) *	2006-08-03	2008-05-15	Tamas Koltai	Polymorphs of solifenacin intermediate
TW200825084A (en) *	2006-11-14	2008-06-16	Astrazeneca Ab	New compounds 521
EP2102200A2 (en) *	2006-11-22	2009-09-23	Medichem, S.A.	An improved process for the synthesis of solifenacin
CZ300692B6 (cs) *	2006-12-22	2009-07-15	Zentiva, A. S.	Zpusob prípravy solifenacinu
CA2682381A1 (en) *	2007-03-30	2008-10-09	Medichem, S.A.	An improved process for the synthesis of solifenacin
EP2146693A2 (en) *	2007-04-11	2010-01-27	Dr. Reddy's Laboratories Ltd.	Solifenacin compositions
JP2009538362A (ja) *	2007-07-13	2009-11-05	テバファーマシューティカルインダストリーズリミティド	ソリフェナシンの調製方法
EP2172201A4 (en) *	2007-07-20	2011-07-06	Astellas Pharma Inc	PHARMACEUTICAL COMPOSITION FOR THE REDUCTION OF LOWER HARNESS SYMPTOMS RELATED TO PROSTATE GAL
EP2018850A1 (en) *	2007-07-24	2009-01-28	Ratiopharm GmbH	Pharmaceutical composition comprising solifenacin or a pharmaceutically acceptable salt thereof
PT2216021E (pt) *	2007-11-02	2012-11-06	Astellas Pharma Inc	Composição farmacêutica para tratar uma bexiga hiperactiva
WO2009087664A1 (en) *	2007-12-04	2009-07-16	Cadila Healthcare Limited	Process for preparing chemically and chirally pure solifenacin base and its salts
WO2009073203A1 (en) *	2007-12-04	2009-06-11	Amgen Inc.	Trp-m8 receptor ligands and their use in treatments
ITMI20080195A1 (it)	2008-02-08	2009-08-09	Dipharma Francis Srl	Procedimento per la preparazione di solifenacin
EP2100599A1 (en)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100598A1 (en)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
AU2009229372C1 (en)	2008-03-27	2017-02-02	Chase Pharmaceuticals Corporation	Use and composition for treating dementia
PL385265A1 (pl) *	2008-05-23	2009-12-07	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Sposób wytwarzania solifenacyny i/lub jej soli o wysokiej czystości farmaceutycznej
PL385264A1 (pl)	2008-05-23	2009-12-07	Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna	Sposób wytwarzania enancjomerycznie czystej (S)-1-fenylo-1, 2, 3, 4-tetrahydroizochinoliny
SI3067353T1 (en)	2008-07-29	2018-03-30	Krka, D.D., Novo Mesto	Process for the preparation of solifenacin salts and their inclusion in pharmaceutical dosage forms
EP2181707A1 (en)	2008-11-04	2010-05-05	Astellas Ireland Co., Ltd.	Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
SI2394648T1 (sl) *	2009-02-04	2017-02-28	Astellas Pharma Inc.	Farmacevtski sestavek za oralno dajanje
ES2753979T3 (es)	2009-03-09	2020-04-15	Megafine Pharma P Ltd	Un nuevo método para la preparación de solifenacina y nuevo intermedio de la misma
WO2010113840A1 (ja)	2009-03-30	2010-10-07	アステラス製薬株式会社	ソリフェナシン非晶質体を含有した固形医薬組成物
WO2011048607A1 (en)	2009-09-25	2011-04-28	Cadila Healthcare Limited	Processes for the preparation of solifenacin or a salt thereof
PL234208B1 (pl)	2010-01-18	2020-01-31	Zakl Farmaceutyczne Polpharma Spolka Akcyjna	Sposób wytwarzania bursztynianu solifenacyny
EP2554184B1 (en)	2010-03-31	2016-10-26	ONO Pharmaceutical Co., Ltd.	Preventive and/or remedy for hand and foot syndrome
EP2563123B1 (en)	2010-04-30	2018-04-25	Merck Sharp & Dohme Corp.	Novel beta 3 adrenergic receptor agonists
KR20130093010A (ko)	2010-05-19	2013-08-21	아스텔라스세이야쿠 가부시키가이샤	솔리페나신 함유 의약 조성물
US8772491B2 (en)	2010-06-28	2014-07-08	Aurobindo Pharma Ltd	Process for the preparation of solifenacin succinate
EP2590973B1 (en)	2010-07-05	2016-08-31	Crystal Pharma, S.A.U.	Solifenacin salts
CA2817336A1 (en)	2010-11-11	2012-05-18	Hexal Ag	Crystalline solifenacin succinate
EP2510928A1 (en)	2011-04-15	2012-10-17	Almirall, S.A.	Aclidinium for use in improving the quality of sleep in respiratory patients
RU2671575C2 (ru)	2011-05-10	2018-11-02	Теравида, Инк.	Применение солифенацина и стимуляторов слюноотделения в лечении гиперактивного мочевого пузыря
WO2012175119A1 (en)	2011-06-22	2012-12-27	Isochem	Process for the preparation of solifenacin and salts thereof
KR101365849B1 (ko)	2012-03-28	2014-02-24	경동제약 주식회사	솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
CN104411687A (zh)	2012-07-02	2015-03-11	法尔玛赞公司	一种用于制备索非那新或其盐的方法
BR112015004244A2 (pt)	2012-08-31	2017-07-04	Astellas Pharma Inc	composição médica oralmente administrada
KR20150048888A (ko)	2012-09-05	2015-05-07	체이스 파마슈티칼스 코포레이션	항콜린 신경보호 조성물 및 그 방법
CN103787969B (zh)	2012-10-30	2016-07-06	上海京新生物医药有限公司	一种(1s)-1-苯基-3,4-二氢-2（1h）-异喹啉甲酸酯的制备方法
WO2014086927A1 (en) *	2012-12-06	2014-06-12	Chiesi Farmaceutici S.P.A.	Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
EP2778167A1 (en)	2013-03-11	2014-09-17	Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi	Stable pharmaceutical composition comprising amorphous solifenacin or its pharmaceutically acceptable salt
KR101823451B1 (ko) *	2013-07-13	2018-01-30	베이징 에프에스웰컴 테크놀로지 디벨롭먼트 컴퍼니 리미티드	퀴논계 화합물, 이의 광학 이성질체 및 이의 제조 방법과 의약 용도
US20170065589A1 (en)	2014-05-06	2017-03-09	Anthony G. Visco	Methods of treating or preventing preterm labor
CN104592221A (zh) *	2015-01-26	2015-05-06	中山奕安泰医药科技有限公司	一种合成索非那新的工艺
KR20160146428A (ko)	2015-06-12	2016-12-21	한미정밀화학주식회사	솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
KR102148414B1 (ko)	2017-05-15	2020-08-26	주식회사 서울제약	솔리페나신을 유효성분으로 하는 구강붕해필름
EP3724188B1 (en)	2017-12-12	2023-06-07	Arkuda Therapeutics	Progranulin modulators and methods of using the same
ES2992256T3 (es)	2018-05-08	2024-12-11	Nippon Shinyaku Co Ltd	Compuestos de azabencimidazol y producto farmacéutico
US20220251084A1 (en) *	2019-06-12	2022-08-11	Arkuda Therapeutics	Progranulin modulators and methods of using the same
CN114929697A (zh)	2019-11-13	2022-08-19	日本新药株式会社	氮杂苯并咪唑化合物和药物
CN113200979A (zh) *	2021-04-13	2021-08-03	上海予君生物科技发展有限公司	一种琥珀酸索非那新的合成工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3687980T2 (de) *	1986-01-07	1993-06-17	Beecham Group Plc	Indolderivate mit einer azabicyclischen seitenkette, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zusammensetzungen.
IT1231238B (it) *	1987-09-21	1991-11-26	Angeli Inst Spa	Derivati ammidinici
IT1228293B (it) *	1989-02-06	1991-06-07	Angeli Inst Spa	Benzoderivati di composti eterociclici contenenti azoto.
IT1230881B (it) *	1989-06-20	1991-11-08	Angeli Inst Spa	Derivati del r(-) 3-chinuclidinolo
GB9023023D0 (en) *	1990-10-23	1990-12-05	Barlow Richard B	Pharmaceutical compositions
GB9202443D0 (en) *	1992-02-05	1992-03-18	Fujisawa Pharmaceutical Co	A novel substituted-acetamide compound and a process for the preparation thereof
JPH076635A (ja) *	1993-06-18	1995-01-10	Sony Corp	信号伝送ケーブル
AU7545894A (en) *	1993-09-02	1995-03-22	Yamanouchi Pharmaceutical Co., Ltd.	Carbamate derivative and medicine containing the same
JPH07258250A (ja) *	1994-03-25	1995-10-09	Yamanouchi Pharmaceut Co Ltd	エステル誘導体
EP1424021B1 (en) *	2002-11-27	2006-09-13	Selmac S.r.l.	Device for positioning and clamping shaped elements and machine equipped with this device

1988
- 1988-09-19 NO NO2005012C patent/NO2005012I1/no unknown
1995
- 1995-12-27 DE DE200412000048 patent/DE122004000048I2/de active Active
- 1995-12-27 JP JP8520367A patent/JP3014457B2/ja not_active Expired - Lifetime
- 1995-12-27 AU AU43553/96A patent/AU695616B2/en not_active Expired
- 1995-12-27 KR KR1019970703649A patent/KR100386487B1/ko not_active Expired - Lifetime
- 1995-12-27 US US08/860,377 patent/US6017927A/en not_active Expired - Lifetime
- 1995-12-27 WO PCT/JP1995/002713 patent/WO1996020194A1/ja not_active Ceased
- 1995-12-27 CN CN95197088A patent/CN1045601C/zh not_active Expired - Lifetime
- 1995-12-27 ES ES95942276T patent/ES2193208T3/es not_active Expired - Lifetime
- 1995-12-27 PL PL95321019A patent/PL182344B1/pl unknown
- 1995-12-27 RU RU97112907/04A patent/RU2143432C1/ru active Protection Beyond IP Right Term
- 1995-12-27 EP EP95942276A patent/EP0801067B1/en not_active Expired - Lifetime
- 1995-12-27 TW TW084113934A patent/TW305842B/zh not_active IP Right Cessation
- 1995-12-27 NL NL300141C patent/NL300141I1/nl unknown
- 1995-12-27 NZ NZ298144A patent/NZ298144A/en not_active IP Right Cessation
- 1995-12-27 MX MX9704880A patent/MX9704880A/es unknown
- 1995-12-27 DK DK95942276T patent/DK0801067T3/da active
- 1995-12-27 PT PT95942276T patent/PT801067E/pt unknown
- 1995-12-27 CA CA002208839A patent/CA2208839C/en not_active Expired - Lifetime
- 1995-12-27 AT AT95942276T patent/ATE233761T1/de active
- 1995-12-27 HU HU9701895A patent/HU223778B1/hu active Protection Beyond IP Right Term
- 1995-12-27 DE DE69529844T patent/DE69529844T2/de not_active Expired - Lifetime
1997
- 1997-06-27 NO NO19973027A patent/NO318026B1/no not_active IP Right Cessation
- 1997-06-27 FI FI972775A patent/FI115631B/fi active Protection Beyond IP Right Term
1999
- 1999-05-14 US US09/312,392 patent/US6174896B1/en not_active Expired - Lifetime
2004
- 2004-12-30 FR FR04C0032C patent/FR04C0032I2/fr active Active
2005
- 2005-01-28 LU LU91133C patent/LU91133I9/fr unknown
- 2005-07-11 NO NO2005016C patent/NO2005016I2/no unknown
2017
- 2017-11-06 NO NO2017055C patent/NO2017055I2/no unknown

Also Published As

Publication number	Publication date
LU91133I9 (en)	2018-08-01
EP0801067A4 (en)	1998-03-11
FI972775A0 (fi)	1997-06-27
NO973027D0 (no)	1997-06-27
CN1045601C (zh)	1999-10-13
RU2143432C1 (ru)	1999-12-27
NO2005012I1 (no)	2005-06-06
LU91133I2 (fr)	2005-03-29
DK0801067T3 (da)	2003-06-30
DE69529844T2 (de)	2004-03-04
CN1171109A (zh)	1998-01-21
NO2005016I2 (no)	2008-02-11
DE122004000048I2 (de)	2006-02-02
NZ298144A (en)	1998-04-27
JP3014457B2 (ja)	2000-02-28
NO2005016I1 (no)	2005-08-29
FR04C0032I1 (no)	2005-02-11
US6174896B1 (en)	2001-01-16
HUT77006A (hu)	1998-03-02
PL321019A1 (en)	1997-11-24
FI115631B (fi)	2005-06-15
HU223778B1 (hu)	2005-01-28
AU695616B2 (en)	1998-08-20
DE69529844D1 (de)	2003-04-10
KR987000303A (ko)	1998-03-30
EP0801067A1 (en)	1997-10-15
JPH09508401A (ja)	1997-08-26
KR100386487B1 (ko)	2003-09-26
NL300141I2 (nl)	2004-04-01
ES2193208T3 (es)	2003-11-01
FR04C0032I2 (fr)	2005-10-21
NO2017055I1 (no)	2017-11-06
NO318026B1 (no)	2005-01-24
NL300141I1 (nl)	2004-04-01
TW305842B (no)	1997-05-21
FI972775A7 (fi)	1997-08-22
CA2208839C (en)	2006-01-31
PL182344B1 (pl)	2001-12-31
WO1996020194A1 (en)	1996-07-04
CA2208839A1 (en)	1996-07-04
ATE233761T1 (de)	2003-03-15
MX9704880A (es)	1997-10-31
NO2017055I2 (no)	2017-11-06
PT801067E (pt)	2003-07-31
US6017927A (en)	2000-01-25
DE122004000048I1 (de)	2005-04-21
AU4355396A (en)	1996-07-19
EP0801067B1 (en)	2003-03-05

Publication	Publication Date	Title
NO973027D0 (no)	1997-06-27	Nye kinuklidinderivater og medisinsk preparat
DE69111138D1 (de)	1995-08-17	Heterocyclische Verbindungen mit antiemetischer und Migräne unterdrückender Wirkung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen.
ATE109484T1 (de)	1994-08-15	Thienopyridin -derivative und diese enthaltende arzneimittel.
NO913087D0 (no)	1991-08-08	Ny tricyklisk forbindelse eller salter derav, fremgangsmaate for fremstilling derav og antimikrobielt middel inneholdende slike.
DE68922537D1 (de)	1995-06-14	Antipsychotische 3-Piperazinylbenzazolderivate.
EA200100916A1 (ru)	2002-02-28	Лекарственное средство, содержащее производное сульфопиранозилацилглицерина
LV11689A (lv)	1997-02-20	4-Ú(2-benzotiazolil)metilamino¾-alfa-Ú(3,4-difluorfenoksi)metil¾-1-piperidinetanols
NO910904D0 (no)	1991-03-07	Fremgangsmaate for fremstilling av en substituert aminforbindelse.
NO985202D0 (no)	1998-11-06	Anti-heliobacter pylori-preparater inneholdende 1-metylcarbapenemderivater
EP0535250A4 (en)	1994-09-28	Novel compounds and use thereof as medicine
DE69300318D1 (de)	1995-09-07	Flavonderivate.
NO180534C (no)	1997-05-07	Nonatetraensyrederivat, farmasöytisk preparat inneholdende dette, og anvendelser av derivatet

Legal Events

Date	Code	Title	Description
2005-08-29	SPCF	Filing of supplementary protection certificate	Free format text: PRODUCT NAME: VESICARE TABLETT, FILMDRASJERT 5 MG OG 10 MG; NAT. REG. NO/DATE: 04-2481, 04-2482 20040819; FIRST REG. NO/DATE: NL , 29151, 29152 20031216 Spc suppl protection certif: 2005016 Filing date: 20050711
2008-02-11	SPCG	Granted supplementary protection certificate	Free format text: PRODUCT NAME: VESICARE TABLETT, FILMDRASJERT 5 MG OG 10 MG; NAT. REG. NO/DATE: 04-2481, 04-2482 20040819; FIRST REG. NO/DATE: NL , 29151, 29152 20031216 Spc suppl protection certif: 2005016 Filing date: 20050711 Extension date: 20181222
2016-01-11	MK1K	Patent expired
2017-11-13	SPCE	Application to extend a supplementary protection certificate (spc)	Free format text: PRODUCT NAME: SOLIFENACIN OG/ELLER ET FARMASOEYTISK SYREADDISJONSSALT DERAV; NAT. REG. NO/DATE: NO , 04-2481, 04-2482 20040819; FIRST REG. NO/DATE: NL , 29151, 29152 20031216; EXPIRATION DATE FOR EXTENSION: 20190622 Spc suppl protection certif: 2017055 Filing date: 20171106
2018-08-13	SPCK	Change in the validity period of an spc	Free format text: EXPIRATION DATE FOR SPC: 20181222 Spc suppl protection certif: 2005016
2018-10-29	SPCH	Extension of a supplementary protection certificate (spc) granted	Free format text: PRODUCT NAME: SOLIFENACIN OG/ELLER ET FARMASOEYTISK SYREADDISJONSSALT DERAV; NAT. REG. NO/DATE: NO , 04-2481, 04-2482 20040819; FIRST REG. NO/DATE: NL , 29151, 29152 20031216; EXPIRATION DATE FOR EXTENSION: 20190622 Spc suppl protection certif: 2017055 Filing date: 20171106
2019-02-11	SPCX	Expiry of an spc	Free format text: PRODUCT NAME: VESICARE TABLETT, FILMDRASJERT 5 MG OG 10 MG; NAT. REG. NO/DATE: 04-2481, 04-2482 20040819; FIRST REG. NO/DATE: NL , 29151, 29152 20031216 Spc suppl protection certif: 2005016 Effective date: 20190204
2019-07-08	SPCZ	Expiry of an extension of a supplementary protection certificate (spc)	Spc suppl protection certif: 2017055